Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dominik Heinzmann

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Pharmaceutical Statistics|August 29, 2019
Integrating phase 2 into phase 3 based on an intermediate endpoint while accounting for a cure proportion-With an application to the design of a clinical trial in acute myeloid leukemiaKaspar Rufibach, Dominik Heinzmann, Annabelle Monnet
Clinical Pharmacokinetics|March 4, 2017
Clinical Pharmacokinetics of VemurafenibWeijiang Zhang, Dominik Heinzmann, Joseph F Grippo
Mathematical Biosciences|September 1, 2009
Compound processes as models for clumped parasite dataDominik Heinzmann, A D Barbour, Paul R Torgerson
Pharmaceutical Statistics|September 2, 2020
A pragmatic adaptive enrichment design for selecting the right target population for cancer immunotherapiesAnh Nguyen Duc, Dominik Heinzmann, Claude Berge, et al.
Frontiers in Pharmacology|February 12, 2024
Applying the estimand and target trial frameworks to external control analyses using observational data: a case study in the solid tumor settingLetizia Polito, Qixing Liang, Navdeep Pal, et al.
Future Oncology (London, England)|August 29, 2014
Neoadjuvant breast cancer treatment as a sensitive setting for trastuzumab biosimilar development and extrapolationChristian Jackisch, Frank A Scappaticci, Dominik Heinzmann, et al.
Veterinary Parasitology|May 23, 2008
An interactive map to assess the potential spread of Lymnaea truncatula and the free-living stages of Fasciola hepatica in SwitzerlandChristina Rapsch, Tobias Dahinden, Dominik Heinzmann, et al.
New Biotechnology|February 25, 2010
A cross-sectional study of biotechnology awareness and teaching in European high schoolsHervé Vanderschuren, Dominik Heinzmann, Carmen Faso, et al.
The Lancet. Oncology|August 14, 2012
Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trialGustavo Ismael, Roberto Hegg, Susanne Muehlbauer, et al.
JAMA Oncology|April 19, 2019
Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer: Final Analysis of the HannaH Phase 3 Randomized Clinical TrialChristian Jackisch, Daniil Stroyakovskiy, Xavier Pivot, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Pharmaceutical Statistics|August 29, 2019
Integrating phase 2 into phase 3 based on an intermediate endpoint while accounting for a cure proportion-With an application to the design of a clinical trial in acute myeloid leukemiaKaspar Rufibach, Dominik Heinzmann, Annabelle Monnet
Clinical Pharmacokinetics|March 4, 2017
Clinical Pharmacokinetics of VemurafenibWeijiang Zhang, Dominik Heinzmann, Joseph F Grippo
Mathematical Biosciences|September 1, 2009
Compound processes as models for clumped parasite dataDominik Heinzmann, A D Barbour, Paul R Torgerson
Pharmaceutical Statistics|September 2, 2020
A pragmatic adaptive enrichment design for selecting the right target population for cancer immunotherapiesAnh Nguyen Duc, Dominik Heinzmann, Claude Berge, et al.
Frontiers in Pharmacology|February 12, 2024
Applying the estimand and target trial frameworks to external control analyses using observational data: a case study in the solid tumor settingLetizia Polito, Qixing Liang, Navdeep Pal, et al.
Future Oncology (London, England)|August 29, 2014
Neoadjuvant breast cancer treatment as a sensitive setting for trastuzumab biosimilar development and extrapolationChristian Jackisch, Frank A Scappaticci, Dominik Heinzmann, et al.
Veterinary Parasitology|May 23, 2008
An interactive map to assess the potential spread of Lymnaea truncatula and the free-living stages of Fasciola hepatica in SwitzerlandChristina Rapsch, Tobias Dahinden, Dominik Heinzmann, et al.
New Biotechnology|February 25, 2010
A cross-sectional study of biotechnology awareness and teaching in European high schoolsHervé Vanderschuren, Dominik Heinzmann, Carmen Faso, et al.
The Lancet. Oncology|August 14, 2012
Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trialGustavo Ismael, Roberto Hegg, Susanne Muehlbauer, et al.
JAMA Oncology|April 19, 2019
Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer: Final Analysis of the HannaH Phase 3 Randomized Clinical TrialChristian Jackisch, Daniil Stroyakovskiy, Xavier Pivot, et al.
Pageof 2